Dr. Pilar Eroles Asensio

Principal Investigator
Research Group on Breast Cancer Biology

Presentation


Dr. Pilar Eroles ─a Miguel Servet researcher of the Carlos III Health Institute joined the Biomedical Research Institute INCLIVA of the Clinical University Hospital of Valencia in 2004. Furthermore, is an associate professor at the Department of Physiology at the University of Valencia and principal co ─ investigator of the Research Group on Breast Cancer Biology.

Her research focusses on the resistance mechanisms to current breast cancer treatments, analyzing the epithelial-mesenchymal transition, epigenetics modifications and the regulation of the tumor microenvironment. The objective of the team is to develop new therapeutic strategies to overcome these resistances, through the combination of biological agents and the development of new treatments like nanoparticles.

She has participated in more than 30 funded projects, being the principal investigator in 9 of them. Her work has been published in prestigious journals like Cancer Cell, Blood, European Journal of Cancer and Oncotarget. Furthermore, she has supervised 9 doctoral thesis and currently she is supervising 2 more, as well as final projects for bachelor and master courses. She is a member of the Research Commission of INCLIVA, she is also a proofreader for various international scientific journals and assessor of the National Agency for Quality Assessment and Accreditation (ANECA).

Dra. Pilar Eroles Asensio
Principal
Investigator
Dr. Pilar Eroles Asensio

pilar.eroles@uv.es

Publications
Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical Anti-HER therapies. Tapia M, Hernando C, Martínez M, Burgués O, Tebar-Sánchez C, Lameirinhas A, Agreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Cancers. 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522. PMID: 37760491

Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. ACS Applied Materials & Interfaces. 2023 Aug 16;15(32):38323-38334. doi: 10.1021/acsami.3c07541. PMID: 37549382

Generation and characterization of trastuzumab/pertuzumab-resistant HER2-Positive breast cancer cell lines. Sanz-Alvarez M, Luque M, Morales-Gallego M, Cristóbal I, Ramírez-Merino N, Rangel Y, Izarzugaza Y, Eroles P, Albanell J, Madoz-Gúrpide J, Rojo F. International Journal of Molecular Sciences. 2023 Dec 22;25(1):207. doi: 10.3390/ijms25010207. PMID: 38203378

High VEGFR3 expression reduces doxorubicin efficacy in triple-negative breast cancer. Torres Ruiz S, Tormo E, Garrido Cano I, Lameirinhas A, Rojo F, Madoz Gurpide J, Burgues O, Hernando C, Bermejo B, Martinez MT, Lluch A, Cejalvo JM, Eroles P. International Journal of Molecular Sciences. 2023 Feb 10;24(4):3601. doi: 10.3390/ijms24043601. PMID: 36835014

miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer. Cabello P, Torres-Ruiz S, Adam-Artigues A, Fores-Martos J, Martinez M, Hernando C, Zazo S, Madoz-Gurpide J, Rovira A, Burgues O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo J, Eroles P. Cancers. 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. PMID: 37046799

Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer. García A, Torres-Ruiz S, Vila L, Villarroel-Vicente C, Bernabeu A, Eroles P, Cabedo N, Cortes D. RSC Medicinal Chemistry. 2023 Oct 4;14(11):2327-2341. doi: 10.1039/d3md00385j. PMID: 38020071

Antagonists of the Mu-opioid receptor in the cancer patient: fact or fiction?. Belltall A, Mazzinari G, Diaz-Cambronero O, Eroles P, Navarro M. Current Oncology Reports. 2022 Oct;24(10):1337-1349. doi: 10.1007/s11912-022-01295-z. PMID: 35648340

CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer. Luque M, Cristobal I, Sanz-Alvarez M, Santos A, Zazo S, Eroles P, Arpi O, Rovira A, Albanell J, Madoz-Gurpide J, Garcia-Foncillas J, Rojo F. Journal of Clinical Medicine. 2022 Mar 14;11(6):1610. doi: 10.3390/jcm11061610. PMID: 35329936

MicroRNAs as a clue to overcome breast cancer treatment resistance. Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. Cancer Metastasis Reviews. 2022 Mar;41(1):77-105. doi: 10.1007/s10555-021-09992-0. PMID: 34524579

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. Cancer Communications. 2022 Dec;42(12):1412-1416. doi: 10.1002/cac2.12352. PMID: 35997029

mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. Casadevall D, Hernandez-Prat A, Garc A-Alonso S, Arpi-Llucia O, Menendez S, Qin M, Guardia C, Morancho B, Sanchez-Mart N F, Zazo S, Gavilan E, Sabbaghi M, Eroles P, Cejalvo J, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Molecular Cancer Research. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. PMID: 35348729

Opioid receptor expression in colorectal cancer: a nested matched case-control study. Belltall A, Mazzinari G, Garrido-Cano I, Giner F, Mari A, Eroles P, Argente-Navarro M, Cata J, Diaz-Cambronero O. Frontiers in Oncology. 2022 Apr 6;12:801714. doi: 10.3389/fonc.2022.801714. PMID: 35463331

Role of SALL4 in HER2+breast cancer progression: regulating PI3K/AKT Pathway. Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgues O, Rovira A, Martinez M, Tapia M, Zazo S, Albanell J, Rojo F, Bermejo B, Eroles P. International Journal of Molecular Sciences. 2022 Oct 31;23(21):13292. doi: 10.3390/ijms232113292. PMID: 36362083

Solid tumor opioid receptor expression and oncologic outcomes: analysis of the cancer genome atlas and genotype tissue expression Project. Belltall A, Zuniga-Trejos S, Garrido-Cano I, Eroles P, Argente-Navarro M, Buggy D, Diaz-Cambronero O, Mazzinari G. Frontiers in Oncology. 2022 Mar 10;12:801411. doi: 10.3389/fonc.2022.801411. PMID: 35359418

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Adam-Artigues A, Arenas E, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martinez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martinez D, Rovira A, Burgues O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Science Advances. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. PMID: 35594351

Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel. Jimenez N, Reig O, Marin-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, Rodriguez-Vida A, Climent MA, Cros S, Chirivella I, Domenech M, Figols M, Gonzalez-Billalabeitia E, Jimenez Peralta D, Rodriguez-Carunchio L, Garcia-Esteve S, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B. Cancers. 2022 Sep 29;14(19):4757. doi: 10.3390/cancers14194757. PMID: 36230681

Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. Fores-Martos J, Cervera-Vidal R, Sierra-Roca J, Lozano-Asencio C, Fedele V, Cornelissen S, Edvarsen H, Tadeo-Cervera I, Eroles P, Lluch A, Tabares-Seisdedos R, Falco A, Van’t Veer LJ, Schmidt M, Quigley DA, Borresen-Dale AL, Kristensen VN, Balmain A, Climent J. NPJ Breast Cancer. 2021 Sep 10;7(1):118. doi: 10.1038/s41523-021-00329-2. PMID: 34508103

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. Adam-Artigues A, Garrido-Cano I, Simon S, Ortega B, Moragon S, Lameirinhas A, Constancio V, Salta S, Burgues O, Bermejo B, Henrique R, Lluch A, Jeronimo C, Eroles P, Cejalvo J. ESMO Open. 2021 Jan 18;6(1):100039. doi: 10.1016/j.esmoop.2020.100039. PMID: 33477007

Expression of phosphorylated BRD4 is markedly associated with the activation status of the PP2A pathway and shows a strong prognostic value in triple negative breast cancer patients. Sanz-Alvarez M, Cristobal I, Luque M, Santos A, Zazo S, Madoz-Gurpide J, Carames C, Chiang C, Garcia-Foncillas J, Eroles P, Albanell J, Rojo F. Cancers. 2021 Mar 12;13(6):1246. doi: 10.3390/cancers13061246. PMID: 33809005

Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez R. ACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: 10.1021/acssensors.0c02222. PMID: 33599490

Oral Selective Estrogen Receptor Degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo J. International Journal of Molecular Sciences. 2021 Jul 22;22(15):7812. doi: 10.3390/ijms22157812. PMID: 34360578

Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer. Guardia C, Bianchini G, Arpi-LLucia O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero J, Soria-Jimenez L, Sabbaghi M, Pena R, Madoz-Gurpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Clinical Cancer Research. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915. PMID:34385295

Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in HER2-positive breast cancer. Luque M, Sanz-Alvarez M, Santamaria A, Zazo S, Cristobal I, de la Fuente L, Minguez P, Eroles P, Rovira A, Albanell J, Madoz-Gurpide J, Rojo F. International Journal of Molecular Sciences. 2021 Dec 10;22(24):13297. doi: 10.3390/ijms222413297. PMID: 34948097

Projects
Reference: PI21/01351
Title: Predicción de enfermedad residual después de la terapia neoadyuvante en cáncer de mama HER2 positivo e identificación de estrategias para superar la resistencia
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Pilar Eroles Asensio
Duration: 2022 – 2024
Total budget: 123.420 €
Reference: PI18/01219
Title: Caracterización y repercusión terapéutica de la ecología de cáncer de mama HER2 positivo
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Pilar Eroles Asensio
Duration: 2019 – 2021
Total budget: 112.530 €
Reference: COST Action CA15204
Title: European Platform for Outcomes Research into Perioperative Interventions during Surgery for Cancer
Funding body: European Commission
Principal Investigator: Pilar Eroles Asensio
Duration: 2016 – 2020
Total budget:
+ Info
Title: Overcoming resistance to HER2 blockade in breast cancer: AXL as a promising druggable target and prognostic biomarker
Doctoral candidate: Adam Artigues, Anna
Director(s): Lluch Hernández, Ana; Eroles Asensio, Pilar
Date of the defense: 12/04/2022
University: Universitat de València

Title: Role of miR-99a-5p in breast cancer: translating molecular findings into clinical tool
Doctoral candidate: Garrido Cano, Iris
Director(s): Eroles Asensio, Pilar; Martínez Máñez, Ramón
Date of the defense: 17/12/2021
University: Universitat Politècnica de València

Title: Involvement of EZH2-MYC loop and SALL4 in epithelial-mesenchymal transition (EMT) and trastuzumab resistance process in HER2+ breast cancer
Doctoral candidate: Pattanayak Pattanayak, Chaudhuri Birlipta
Director(s): Eroles Asensio, Pilar; Cejalvo Andújar, Juan Miguel
Date of the defense: 26/02/2021
University: Universitat de València

Title: Epigenetic regulation of resistance to treatments in triple negative and HER2+ breast cancer: mirnas involved
Doctoral candidate: Cabello Navarro, Paula
Director(s): Erolés Asensio, Pilar; Lluch Hernández, Ana
Date of the defense: 28/09/2020
University: Universitat Politècnica de València